DAIICHI SANKYO COMPANY shares hold firm after ENHERTU combination therapy receives partial approval in Europe
Shares of DAIICHI SANKYO COMPANY, LIMITED <4568> held firm after announcing on the 1st that it received partial variation approval in the European Union for combination therapy of its cancer drug ENHERTU (trastuzumab deruxtecan) and pertuzumab as a first-line treatment for breast cancer. The news supported the stock. In connection with the approval, DAIICHI SANKYO will receive a $100 million development milestone payment from AstraZeneca
Source: MINKABU PRESS
*Translated by generative AI. Click here for the original article.
Related Articles
-
Sekisui Jushi holds firm as company to book gain on sale of SHIKOKU KASEI HOLDINGS CORPORATION <4099> shares
Wed Sep 2, 2026 2:31 pm JST Catalyst -
Daiwa rebounds sharply after 5 sessions on expectations of earnings improvement from Kanazawa New Grand Hotel sale
Wed Sep 2, 2026 2:18 pm JST Catalyst -
jig.jp tops 'rising buy forecasts' ranking on Minkabu individual investor survey
Wed Sep 2, 2026 2:19 pm JST Catalyst -
Zenken shares hold firm as employee review platform 'VOiCE' surpasses 500 corporate clients
Wed Sep 2, 2026 2:05 pm JST Catalyst -
Market breadth at 2 p.m.: 107 gainers vs. 1,421 decliners on TSE Prime
Wed Sep 2, 2026 2:04 pm JST Market -
Nisshinbo Holdings holds firm as company plans to book extraordinary gain on partial sale of SHIKOKU KASEI HOLDINGS CORPORATION <4099> shares
Wed Sep 2, 2026 1:35 pm JST Catalyst -
Future Innovation Group briefly turns positive after subsidiary secures cashless payment contract with Shinjuku Ward
Wed Sep 2, 2026 1:31 pm JST Catalyst -
FIT EASY edges lower despite strong monthly KPIs
Wed Sep 2, 2026 1:43 pm JST Catalyst -
Open Up Group trims afternoon losses after announcing capital and business tie-up with AI HR service provider PeopleX
Wed Sep 2, 2026 1:33 pm JST Catalyst -
First TOPIX periodic rebalancing expected to add McDonald Japan, GO Inc, Trial Holdings among new inclusions, major domestic brokerages forecast
Wed Sep 2, 2026 1:52 pm JST Catalyst